mProX™ Human FGFR4 Stable Cell Line

Product Information

Target Protein

FGFR4

Target Family

Kinases/Enzyme Drug Discovery Assays and Products

Target Protein Species

Human

Host Cell Type

HUH7; HEP3B; HEPG2; CHO-K1; HEK293

Target Classification

Kinase Cell Lines

Target Research Area

Cancer Research

Related Diseases

Rhabdomyosarcoma and Breast Cancer. Among its related pathways are Apoptotic Pathways in Synovial Fibroblasts and Downstream signaling of activated FGFR2

Gene ID

2264

UniProt ID

P22455

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

In humans, the FGFR4 gene encodes the protein known as fibroblast growth factor receptor 4. Another designation for FGFR4 is CD334. The fibroblast growth factor receptor family, whose members' amino acid sequences have been extensively conserved both among themselves and throughout evolution, includes the protein that this gene encodes. Members of the FGFR family exhibit variations in their tissue distribution and ligand affinity. A complete representative protein would have three immunoglobulin-like domains in its extracellular portion, one hydrophobic membrane-spanning segment, and a cytoplasmic tyrosine kinase domain. The protein's extracellular component interacts with growth factors for fibroblasts, initiating a series of downstream signals that ultimately affect mitogenesis and differentiation. The customized FGFR4 stable cell line can be used in antibody discovery and development, potential drug candidate screening and signaling pathway researches.

Protocols

Please visit our protocols page.

Customer Reviews

chat William

This FGFR4 cell line is sensitive and specific. I definitely recommend this cell line. Jul 28 2020

chat Verified Customer

chat Amanda

I must say that I am extremely impressed with its performance. The FGFR4 cell line was easy to use and provided excellent results in my experiments. Jan 19 2020

chat Verified Customer

FAQ

Any questions about our products? Please visit our frequently asked questions page.

Published Data

Fig.1 FGFR4 expression levels in 6 HCC cell lines.

By using RT-PCR and western blot analysis to measure the FGFR4 protein and mRNA levels in six HCC cells, it was discovered that HUH7, HEP3B, and HEPG2 cells had overexpressed FGFR4.

Ref: Nam, Yunju, et al. "Anti-cancer effects of 3, 4-dihydropyrimido [4, 5-d] pyrimidin-2 (1H)-one derivatives on hepatocellular carcinoma harboring FGFR4 activation." Neoplasia 24.1 (2022): 34-49.

Pubmed: 34864570

DOI: 10.1016/j.neo.2021.11.011

Research Highlights

An FGFR4 inhibitor may be effective in treating about one-third of HCC patients whose tumors produce FGF19 in addition to FGFR4 and its coreceptor klotho β (KLB). These results represent the first instance of a treatment approach that specifically targets a subset of HCC patients.
Hagel, Margit, et al. "First selective small molecule inhibitor of FGFR4 for the treatment of hepatocellular carcinomas with an activated FGFR4 signaling pathway." Cancer discovery 5.4 (2015): 424-437.
Pubmed: 25776529 DOI: 10.1158/2159-8290.CD-14-1029

An increasing body of research suggests that FGFR4 plays a significant and distinct role in the development of tumors, their ability to resist anti-tumor therapy, and the oncogenesis of various cancer types.
Levine, Kevin M., et al. "FGFR4: A promising therapeutic target for breast cancer and other solid tumors." Pharmacology & therapeutics 214 (2020): 107590.
Pubmed: 32492514 DOI: 10.1016/j.pharmthera.2020.107590